Bagcchi S. WHO’s 2024 tips to fight hepatitis B. Lancet Infect Dis. 2024;24: e360.
Hsu YC, Huang DQ, Nguyen MH. World burden of hepatitis B virus: present standing, missed alternatives and a name for motion. Nat Rev Gastroenterol Hepatol. 2023;20:524–37.
Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Grey R, Lim YS, Chen CJ, Ocama P, Desalegn H, Abbas Z. World prevalence, cascade of care, and prophylaxis protection of hepatitis B in 2022: a modelling examine. Lancet Gastroenterol Hepatol. 2023;8:879–907.
Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A world scientific technique to remedy hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–58.
Yuen M-F, Chen D-S, Dusheiko GM, Janssen HL, Lau DT, Locarnini SA, et al. Hepatitis B virus an infection. Nat Rev Dis Primers. 2018;4:1–20.
Liaw Y-F, Chu C-M. Hepatitis B virus an infection. Lancet. 2009;373:582–92.
Trépo C, Chan HL, Lok A. Hepatitis B virus an infection. Lancet. 2014;384:2053–63.
Tang LS, Covert E, Wilson E, Kottilil S. Continual hepatitis B an infection: a evaluate. JAMA. 2018;319:1802–13.
Busch Okay, Thimme R. Pure historical past of power hepatitis B virus an infection. Med Microbiol Immunol. 2015;204:5–10.
Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Threat elements for the event of hepatocellular carcinoma (HCC) in power hepatitis B virus (HBV) an infection: a scientific evaluate and meta-analysis. J Viral Hepatitis. 2021;28:493–507.
Lampertico P, Agarwal Okay, Berg T, Buti M, Janssen HL, Papatheodoridis G, et al. EASL 2017 Scientific Follow Pointers on the administration of hepatitis B virus an infection. Hepatology. 2017;67:370–98.
Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, et al. Impact on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos (t) ide analogue remedy versus nucleos (t) ide analogue remedy alone in sufferers with HBe antigen-negative power hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, managed, open-label trial. Lancet. 2017;2:177–88.
Chen VL, Yeh ML, Le AK, Jun M, Saeed WK, Yang JD, et al. Anti-viral remedy is related to improved survival however is underutilised in sufferers with hepatitis B virus-related hepatocellular carcinoma: real-world east and west expertise. Aliment Pharmacol Ther. 2018;48:44–54.
Nguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, et al. Poor adherence to tips for therapy of power hepatitis B virus an infection at main care and referral practices. Clin Gastroenterol Hepatol. 2019;17:957-967.e957.
Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, et al. Section IV randomized medical examine: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive power hepatitis B. J Formosan Med Assoc. 2018;117:588–97.
Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, et al. Sequential mixture remedy with pegylated interferon results in lack of hepatitis B floor antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive power hepatitis B sufferers receiving long-term entecavir therapy. Antimicrob Brokers Chemother. 2015;59:4121–8.
Qureshi A, Tantray VG, Kirmani AR, Ahangar AG. A evaluate on present standing of antiviral siRNA. Rev Med Virol. 2018;28: e1976.
de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with illness: a progress report on siRNA-based therapeutics. Nat Rev Drug Discovery. 2007;6:443–53.
Sajid MI, Moazzam M, Cho Y, Kato S, Xu A, Method JJ, et al. siRNA therapeutics for the remedy of COVID-19 and different coronaviruses. Mol Pharm. 2021;18:2105–21.
Mehta A, Michler T, Merkel OM. siRNA therapeutics towards respiratory viral infections-what have we discovered for potential COVID-19 therapies? Adv Healthcare Mater. 2021;10: e2001650.
Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, et al. Small interfering RNA (siRNA)-based therapeutic functions towards viruses: ideas, potential, and challenges. J Biomed Sci. 2023;30:88.
van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-based remedy for hepatitis B virus an infection. Viruses. 2020;12:851.
Roca Suarez AA, Testoni B, Zoulim F. HBV 2021: New therapeutic methods towards an previous foe. Liver Int. 2021;41(Suppl 1):15–23.
Hui RW, Mak LY, Seto WK, Yuen MF. Therapeutic advances in HBV remedy. Scientific liver illness. 2024;23: e0161.
Hui RW, Mak LY, Seto WK, Yuen MF. RNA interference as a novel therapy technique for power hepatitis B an infection. Clin Mol Hepatol. 2022;28:408–24.
Lee SJ, Son S, Yhee JY, Choi Okay, Kwon IC, Kim SH, et al. Structural modification of siRNA for environment friendly gene silencing. Biotechnol Adv. 2013;31:491–503.
Chisari FV, Ferrari C, Mondelli MU. Hepatitis B virus construction and biology. Microb Pathog. 1989;6:311–25.
Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic methods for hepatitis B virus an infection: in the direction of a remedy. Nat Rev Drug Discovery. 2019;18:827–44.
Locarnini S, Littlejohn M, Aziz MN, Yuen L. Doable origins and evolution of the hepatitis B virus (HBV). Semin Most cancers Biol. 2013;23:561–75.
Seeger C, Mason WS. Molecular biology of hepatitis B virus an infection. Virology. 2015;479:672–86.
Venkatakrishnan B, Zlotnick A. The structural biology of hepatitis B virus: type and performance. Annu Rev Virol. 2016;3:429–51.
Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Latest Advances in Hepatitis B Therapy. Prescription drugs. 2021;14:417.
Wei L, Ploss A. Core parts of DNA lagging strand synthesis equipment are important for hepatitis B virus cccDNA formation. Nat Microb. 2020;5:715–26.
Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation. Viruses. 2021;13:1463.
Ligat G, Goto Okay, Verrier E, Baumert TG. Focusing on viral cccDNA for remedy of power hepatitis B. Curr Hepatol Rep. 2020;19:235–44.
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Management of cccDNA operate in hepatitis B virus an infection. J Hepatol. 2009;51:581–92.
Nassal M, Schaller H. Hepatitis B virus replication. Tendencies Microbiol. 1993;1:221–8.
Tsukuda S, Watashi Okay. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182: 104925.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a useful receptor for human hepatitis B and D virus. Elife. 2012;1: e00049.
Asami J, Park JH, Nomura Y, Kobayashi C, Mifune J, Ishimoto N, et al. Structural foundation of hepatitis B virus receptor binding. Nat Struct Mol Biol. 2024;31:447–54.
Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex type of the hepadnavirus genome exists in situ as a heterogeneous inhabitants of viral minichromosomes. J Virol. 1995;69:3350–7.
Nassal M. HBV cccDNA: viral persistence reservoir and key impediment for a remedy of power hepatitis B. Intestine. 2015;64:1972–84.
Glebe D, Bremer CM, editors. The molecular virology of hepatitis B virus. Seminars in liver illness; 2013: Thieme Medical Publishers.
Ghaemi Z, Nafiu O, Tajkhorshid E, Gruebele M, Hu J. A computational spatial whole-Cell mannequin for hepatitis B viral an infection and drug interactions. Sci Rep. 2023;13:21392.
Cornberg M, Lok AS-F, Terrault NA, Zoulim F, Berg T, Brunetto MR, et al. Steering for design and endpoints of medical trials in power hepatitis B-Report from the 2019 EASL-AASLD HBV Therapy Endpoints Convention. Hepatology. 2020;72:539–57.
Gopalakrishna H, Ghany MG. Perspective on rising therapies to realize useful remedy of power hepatitis B. Curr Hepatol Rep. 2024;23:1–12.
Jeng W-J, Lok AS. What’s going to it take to remedy hepatitis B? Hepatol Commun. 2023;7: e0084.
Calvaruso V, Craxì A. Fibrosis in power viral hepatitis. Greatest Pract Res Clin Gastroenterol. 2011;25:219–30.
Allweiss L, Dandri M. The position of cccDNA in HBV upkeep. Viruses. 2017;9:156.
Wong GLH, Gane E, Lok ASF. The best way to obtain useful remedy of HBV: stopping NUCs, including interferon or new drug growth? J Hepatol. 2022;76:1249–62.
Isorce N, Lucifora J, Zoulim F, Durantel D. Immune-modulators to fight hepatitis B virus an infection: from IFN-α to novel investigational immunotherapeutic methods. Antiviral Res. 2015;122:69–81.
Baltayiannis G, Karayiannis P. Therapy choices past IFNα and NUCs for power HBV an infection: expectations for tomorrow. J Viral Hepatitis. 2014;21:753–61.
Yuen M-F, Seto W-Okay, Chow DH-F, Tsui Okay, Wong DK-H, Ngai VS, et al. Lengthy-term lamivudine remedy reduces the chance of long-term problems of power hepatitis B an infection even in sufferers with out superior illness. Antiviral Ther. 2007;12:1295–304.
Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impression of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in sufferers with power hepatitis. B Most cancers. 2015;121:3631–8.
Yardeni D, Chang KM, Ghany MG. Present finest follow in hepatitis b administration and understanding long-term prospects for remedy. Gastroenterology. 2023;164:42-60.e46.
Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the therapy of power hepatitis B. J Clin Med. 2020;9:3187.
Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44:593–606.
Gupta N, Goyal M, Wu CH, Wu GY. The molecular and structural foundation of HBV-resistance to nucleos(t)ide analogs. J Clin Transl Hepatol. 2014;2:202–11.
Lin CL, Kao JH. Latest advances within the therapy of power hepatitis B. Knowledgeable Opin Pharmacother. 2011;12:2025–40.
Qu B, Brown RJ. Methods to inhibit Hepatitis B Virus on the transcript degree. Viruses. 2021;13:1327.
Dusheiko G, Agarwal Okay, Maini MK. New approaches to power hepatitis B. N Engl J Med. 2023;388:55–69.
Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a steady HBV-producing cell line. Hepatology. 2003;38:842–50.
Kasianchuk N, Dobrowolska Okay, Harkava S, Bretcan A, Zarębska-Michaluk D, Jaroszewicz J, et al. Gene-editing and RNA interference in treating hepatitis B: a evaluate. Viruses. 2023;15:2395.
Watanabe T, Hayashi S, Tanaka YJV. Drug discovery examine geared toward a useful remedy for HBV. Viruses. 2022;14:1393.
Ryther RC, Flynt AS, Phillips JA third, Patton JG. siRNA therapeutics: huge potential from small RNAs. Gene Ther. 2005;12:5–11.
Grünweller A, Hartmann RK. RNA interference as a gene-specific method for molecular medication. Curr Med Chem. 2005;12:3143–61.
Rana TM. Illuminating the silence: understanding the construction and performance of small RNAs. Nat Rev Mol Cell Biol. 2007;8:23–36.
Macrae IJ, Zhou Okay, Li F, Repic A, Brooks AN, Cande WZ, et al. Structural foundation for double-stranded RNA processing by Dicer. Science. 2006;311:195–8.
Kurreck J. siRNA effectivity: construction or sequence-that is the query. J Biomed Biotechnol. 2006;2006:83757.
Sneller L, Lin C, Worth A, Kottilil S, Chua JVJM. RNA interference therapeutics for power hepatitis B: progress challenges, and future prospects. Microorganisms. 2024;12:599.
Sajid MI, Moazzam M, Kato S, Yeseom Cho Okay, Tiwari RK. Overcoming BARRIERS for siRNA therapeutics: from bench to bedside. Prescription drugs. 2020;13:294.
Van den Berg FT. Optimisation of expressed RNA interference mimics utilizing predicted stem size: College of the Witwatersrand, School of Science, Faculty of Molecular and Cell Biology. 2016.
Wittrup A, Lieberman J. Flattening illness: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16:543–52.
Nayagam JS, Cargill ZC, Agarwal KJCHR. The position of RNA interference in useful remedy methods for power hepatitis B. Curr Hepatol Rep. 2020;19:362–9.
Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and useful outlook. ChemMedChem. 2010;5:328–49.
Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4: e252.
Wang P, Zhou Y, Richards AMJT. Efficient instruments for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Theranostics. 2021;11:8771.
Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and techniques to cut back off-target results. Entrance Plant Sci. 2021;11: 526455.
Setten RL, Rossi JJ, Han S. The present state and future instructions of RNAi-based therapeutics. Na Rev Drug Discov. 2019;18:421–46.
Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genetic. 2006;2: e140.
Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotech. 2004;22:326–30.
Gish RG, Yuen M-F, Chan HLY, Given BD, Lai C-L, Locarnini SA, et al. Artificial RNAi triggers and their use in power hepatitis B therapies with healing intent. Antiviral Res. 2015;121:97–108.
Yu X. Identification of host elements regulating hepatitis B virus covalently closed round DNA transcription: College of Pittsburgh; 2024.
Okada H, Sakamoto T, Nio Okay, Li Y, Kuroki Okay, Sugimoto S, et al. Lipid nanoparticle-encapsulated DOCK11-siRNA effectively reduces hepatitis B virus cccDNA degree in contaminated mice. Mol Ther Strategies Clin Dev. 2024;32: 101289.
Mohd-Ismail NK, Lim Z, Gunaratne J, Tan Y-J. Mapping the interactions of HBV cccDNA with host elements. J Mol Sci. 2019;20:4276.
Allweiss L, Giersch Okay, Pirosu A, Volz T, Muench RC, Beran RK, et al. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complicated and silencing of the viral genome in vivo. Intestine. 2022;71:372–81.
Li Y-Y, Murai Okay, Lyu J, Honda MJV. Roles performed by DOCK11, a Guanine nucleotide trade issue, in HBV entry and persistence in hepatocytes. Viruses. 2024;16:745.
Grassi M, Cavallaro G, Scirè S, Scaggiante B, Dapas B, Farra R, et al. Present methods to enhance the efficacy and the supply of nucleic acid primarily based medication. Curr Sign Transduct Ther. 2010;5:92–120.
Farra R, Musiani F, Perrone F, Čemažar M, Kamenšek U, Tonon F, et al. Polymer-mediated supply of siRNAs to hepatocellular carcinoma: variables affecting specificity and effectiveness. Molecules. 2018;23:777.
Barba AA, Cascone S, Caccavo D, Lamberti G, Chiarappa G, Abrami M, et al. Engineering approaches in siRNA supply. Int J Pharm. 2017;525:343–58.
Shegokar R, Al Shaal L, Mishra PR. SiRNA supply: challenges and position of provider methods. Pharmazie. 2011;66:313–8.
Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, et al. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011;19:381–5.
Paunovska Okay, Loughrey D, Dahlman JE. Drug supply methods for RNA therapeutics. Nat Rev Genet. 2022;23:265–80.
Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, et al. siRNA: mechanism of motion, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905: 174178.
Wang J, Lu Z, Wientjes MG, Au JL. Supply of siRNA therapeutics: limitations and carriers. AAPS J. 2010;12:492–503.
Li L, Shen Y. Overcoming obstacles to develop efficient and secure siRNA therapeutics. Knowledgeable Opin Biol Ther. 2009;9:609–19.
Juliano R, Bauman J, Kang H, Ming X. Organic limitations to remedy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6:686–95.
Gavrilov Okay, Saltzman WM. Therapeutic siRNA: ideas, challenges, and techniques. Yale J Biol Med. 2012;85:187–200.
Kaneda Y. Gene remedy: a battle towards organic limitations. Curr Mol Med. 2001;1:493–9.
Morrissey DV, Lockridge JA, Shaw L, Blanchard Okay, Jensen Okay, Breen W, et al. Potent and protracted in vivo anti-HBV exercise of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–7.
Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Cur Protocols Nucleic Acid Chem. 2009. https://doi.org/10.1002/0471142700.nc1603s39.
Chernikov IV, Ponomareva UA, Chernolovskaya EL. Structural modifications of siRNA enhance its efficiency in vivo. Int J Mol Sci. 2023;24:956.
Gaglione M, Messere A. Latest progress in chemically modified siRNAs. Mini Rev Med Chem. 2010;10:578–95.
Joo MK, Yhee JY, Kim SH, Kim Okay. The potential and advances in RNAi remedy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J Managed Rel. 2014;193:113–21.
Ku SH, Jo SD, Lee YK, Kim Okay, Kim SH. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev. 2016;104:16–28.
Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based remedy. Nat Rev Genet. 2014;15:541–55.
Van de Vyver T, De Smedt SC, Raemdonck Okay. Modulating intracellular pathways to enhance non-viral supply of RNA therapeutics. Adv Drug Deliv Rev. 2022;181: 114041.
Liu Z, Wang S, Tapeinos C, Torrieri G, Känkänen V, El-Sayed N, et al. Non-viral nanoparticles for RNA interference: ideas of design and sensible tips. Adv Drug Deliv Rev. 2021;174:576–612.
Yan Y, Liu X-Y, Lu A, Wang X-Y, Jiang L-X, Wang J-C. Non-viral vectors for RNA supply. J Management Launch. 2022;342:241–79.
Tong L, Liu D, Cao Z, Zheng N, Mao C, Liu S, et al. Analysis standing and prospect of non-viral vectors primarily based on siRNA: a evaluate. Int J Mol Sci. 2023;24:3375.
Gao Okay, Huang L. Nonviral strategies for siRNA supply. Mol Pharm. 2009;6:651–8.
David S, Pitard B, Benoît J-P, Passirani C. Non-viral nanosystems for systemic siRNA supply. Pharmacol Res. 2010;62:100–14.
Zhang J, Li X, Huang L. Non-viral nanocarriers for siRNA supply in breast most cancers. J Managed Launch. 2014;190:440–50.
Thomas M, Lu JJ, Chen J, Klibanov AM. Non-viral siRNA supply to the lung. Adv Drug Deliv Rev. 2007;59:124–33.
Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, et al. Security, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the therapy of power hepatitis B virus an infection, in wholesome volunteers. Clin Pharm Drug Dev. 2017;6:350–62.
Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, et al. RNA interference remedy with ARC-520 leads to extended hepatitis B floor antigen response in sufferers with power hepatitis B an infection. Hepatology. 2020;72:19–31.
Gane E, Locarnini S, Lim TH, Strasser S, Sievert W, Cheng W, et al. Quick-term therapy with RNA interference remedy, JNJ-3989, leads to sustained hepatitis B floor antigen suppression in sufferers with power hepatitis B receiving nucleos (t) ide analogue therapy. J Hepatol. 2020. https://doi.org/10.1016/S0168-8278(20)30597-3.
Agarwal Okay, Gane E, Cheng W, Sievert W, Roberts SK, Ahn SH, et al. HBcrAg, HBV-RNA declines in a section 2a examine evaluating the multi-dose exercise of ARB-1467 in HBeAg-positive and destructive virally suppressed topics with hepatitis B. J Hepatol. 2017;66:S688.
Streinu-Cercel A, Gane E, Cheng W, Sievert W, Roberts S, Ahn S, et al. A section 2a examine evaluating the multi-dose exercise of ARB-1467 in HBeAg constructive and destructive virally suppressed topics with hepatitis B. J Hepatol. 2017;1:S688–9.
Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, et al. Scientific and preclinical single-dose pharmacokinetics of VIR-2218, an RNAi therapeutic concentrating on HBV an infection. Medication R&D. 2021;21:455–65.
Thi EP, Yuen R, Gane E, Sevinsky H, Sims Okay, Anderson M, et al., editors. Inhibition of hepatitis B floor antigen by RNA interference therapeutic AB-729 in power hepatitis B sufferers correlates with suppression of all HBsAg isoforms and HBV RNA. The Worldwide Liver Congress 2021 (ILC 2021); 2021: Elsevier BV. The Journal’s website is situated at http://www.elsevier.com
Yuen MF, Lim TH, Kim W, Tangkijvanich P, Yoon J-H, Sievert W, et al., editors. HBV RNAi inhibitor RG6346 in Section 1b-2a trial was secure, well-tolerated, and resulted in substantial and sturdy reductions in serum HBsAg ranges. The Liver Assembly Digital Expertise™; 2020: AASLD.
Seto W-Okay, Liang Z, Gan LM, Fu J, Yuen M-F. Security and antiviral exercise of RBD1016, a RNAi therapeutic, in Chinese language topics with power hepatitis B virus (HBV) an infection. J Hepatol. 2023;78:S1152.
Springer AD, Dowdy SF. GalNAc-siRNA conjugates: main the way in which for supply of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109–18.
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Focused supply of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18:1357–64.
Korin E, Bejerano T, Cohen S. GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA concentrating on to the liver. J Management Launch. 2017;266:310–20.
Ikeda Y, Taira Okay. Ligand-targeted supply of therapeutic siRNA. Pharm Res. 2006;23:1631–40.
Perrone F, Craparo EF, Cemazar M, Kamensek U, Drago SE, Dapas B, et al. Focused supply of siRNAs towards hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer. J Managed Launch. 2021;330:1132–51.
Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, et al. Scientific proof of idea for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017;25:71–8.
Vermeulen LM, De Smedt SC, Remaut Okay, Braeckmans Okay. The proton sponge speculation: fable or reality? Eur J Pharm Biopharm. 2018;129:184–90.
Creusat G, Rinaldi A-S, Weiss E, Elbaghdadi R, Remy J-S, Mulherkar R, et al. Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA supply methods. Bioconjug Chem. 2010;21:994–1002.
Lewis DL. Dynamic polyconjugates ( DPC ) expertise : a chic answer to the siRNA supply downside. 2011.
Wong SC, Klein JJ, Hamilton HL, Chu Q, Frey CL, Trubetskoy VS, et al. Co-injection of a focused, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012;22:380–90.
Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, et al. Hepatocyte-targeted RNAi therapeutics for the therapy of power hepatitis B virus an infection. Mol Ther. 2013;21:973–85.
Ranjbar S, Zhong XB, Manautou J, Lu X. A holistic evaluation of the intrinsic and delivery-mediated toxicity of siRNA therapeutics. Adv Drug Deliv Rev. 2023;201: 115052.
Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic polyconjugates for focused in vivo supply of siRNA to hepatocytes. Proc Natl Acad Sci USA. 2007;104:12982–7.
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: cutting-edge. Sign Transduct Goal Ther. 2020;5:101.
Noticed PE, Tune E-W. siRNA therapeutics: a medical actuality. Sci China Life Sci. 2020;63:485–500.
Paul A, Muralidharan A, Biswas A, Kamath BV, Joseph A, Alex ATJO. siRNA therapeutics and its challenges: latest advances in efficient supply for most cancers remedy. OpenNano. 2022;7: 100063.
Thangamani L, Balasubramanian B, Easwaran M, Natarajan J, Pushparaj Okay, Meyyazhagan A, et al. GalNAc-siRNA conjugates: potential instruments on the frontier of anti-viral therapeutics. Pharmacol Res. 2021;173: 105864.
Nair JK, Willoughby JL, Chan A, Charisse Okay, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits sturdy RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958–61.
Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, et al. Choice of GalNAc-conjugated siRNAs with restricted off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.
Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Supply of oligonucleotides to the liver with GalNAc: from analysis to registered therapeutic drug. Mol Ther. 2020;28:1759–71.
Lu M, Zhang M, Hu B, Huang Y. siRNA design and GalNAc-empowered hepatic focused supply. Design and Supply of SiRNA therapeutics. 2021:77–100.
Kandasamy P, Mori S, Matsuda S, Erande N, Datta D, Willoughby JL, et al. Metabolically steady anomeric linkages containing GalNAc–siRNA conjugates: an interaction amongst ASGPR, glycosidase, and RISC pathways. J Med Chem. 2023;66:2506–23.
Huang X, Leroux J-C, Castagner B. Effectively-defined multivalent ligands for hepatocytes concentrating on through asialoglycoprotein receptor. Bioconjug Chem. 2017;28:283–95.
Scharner J, Qi S, Rigo F, Bennett CF, Krainer AR. Supply of GalNAc-conjugated splice-switching ASOs to non-hepatic cells by way of ectopic expression of asialoglycoprotein receptor. Mol Ther Nucleic Acids. 2019;16:313–25.
Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian Okay, et al. Superior siRNA designs additional enhance in vivo efficiency of GalNAc-siRNA conjugates. Mol Ther. 2018;26:708–17.
Nair JK, Attarwala H, Sehgal A, Wang Q, Aluri Okay, Zhang X, et al. Impression of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates. Nucleic Acids Res. 2017;45(19):10969–77.
Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The present panorama of nucleic acid therapeutics. Nat Nanotech. 2021;16:630–43.
Schlegel MK, Janas MM, Jiang Y, Barry JD, Davis W, Agarwal S, et al. From bench to bedside: bettering the medical security of GalNAc–siRNA conjugates utilizing seed-pairing destabilization. Nucleic Acids Res. 2022;50:6656–70.
Macron D. Arrowhead presents preclinical knowledge on HBV candidate, subcutaneous supply tech. Gene Silencing Information. 2012.
Yuen M-F, Chan HL-Y, Given B, Hamilton J, Schluep T, Lewis DL, et al. Section II, dose ranging examine of ARC-520, a siR-NA-based therapeutic, in sufferers with power hepatitis B virus an infection: LB-21. Hepatology. 2014;60:1280A.
Yuen M-F, Wong DK-H, Schluep T, Lai C-L, Ferrari C, Locarnini S, et al. Lengthy-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese language power hepatitis B sufferers on entecavir therapy. Intestine. 2022;71:789–97.
Rozema DB, Blokhin AV, Wakefield DH, Benson JD, Carlson JC, Klein JJ, et al. Protease-triggered siRNA supply autos. J Management Launch. 2015;209:57–66.
Gane EJ, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, et al., editors. Dose response with the RNA interference (RNAi) remedy JNJ-3989 mixed with nucleos (t) ide analogue (NA) therapy in expanded cohorts of sufferers (PTS) with power hepatitis B (CHB). The seventieth Annual Assembly of the American Affiliation for the Examine of Liver Illnesses (AASLD): The Liver Assembly 2019; 2019: John Wiley & Sons, Inc.
Yuen M-F, Locarnini S, Given B, Schluep T, Hamilton J, Biermer M, et al. First medical expertise with RNA interference-based triple mixture remedy in power hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos (t) ide analogue. Hepatology. 2019;70:1489A.
Li H, Niu X, Zhang Y, Zhang D, Zhang Y, Wang L, et al. Pharmacokinetics, security, and tolerability of the siRNA JNJ-73763989 in wholesome Chinese language grownup members. Clin Pharmacol Drug Dev. 2023;12:175–80.
Yuen M-F, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, et al. Mixture remedies together with the small-interfering RNA JNJ-3989 induce fast and typically extended viral responses in sufferers with CHB. J Hepatol. 2022;77:1287–98.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, et al. Efficacy and security of the siRNA JNJ-73763989 and the capsid meeting modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the therapy of power hepatitis B virus an infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, section 2b trial. Lancet Gastroenterol Hepatol. 2023;8:790–802.
Yuen M-F, Berliba E, Kim YJ, Holmes JA, Lim Y-S, Strasser SI, et al., editors. Security and pharmacodynamics of the GalNAc-siRNA AB-729 in topics with power hepatitis B an infection. The Liver Assembly Digital Expertise™; 2020: AASLD.
Gane E, Yuen M, Anderson M, Cloherty G, Thi E, Wattamwar P, et al. A single dose of the GalNAc-siRNA AB-729 leads to extended reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA within the absence of nucleos (t) ide analogue remedy in HBeAg-subjects with power hepatitis B an infection PO2879. 2021.
Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, et al. Analysis of RNAi therapeutics VIR-2218 and ALN-HBV for power hepatitis B: outcomes from randomized medical trials. J Hepatol. 2023;79:924–32.
Hui RW-H, Mak LY, Seto W-Okay, Yuen M-F. Assessing the growing pharmacotherapeutic panorama in hepatitis B therapy: a highlight on medication at section II medical trials. Knowledgeable Opin Emerg Medication. 2022;27(2):127–40.
Tan YC, Lee GH, Huang DQ, Lim SG. Future anti-HDV therapy methods, together with these geared toward HBV useful remedy. Liver Int. 2022. https://doi.org/10.1111/liv.15387.
Gane EJ, Kim W, Lim TH, Tangkijvanich P, Yoon J-H, Sievert W, et al. First-in-human randomized examine of RNAi therapeutic RG6346 for power hepatitis B virus an infection. J Hepatol. 2023;79:1139–49.
Aibani N, Khan TN, Callan B. Liposome mimicking polymersomes; a comparative examine of the deserves of polymersomes by way of formulation and stability. Int J Pharm. 2020;2: 100040.
Tenchov R, Chicken R, Curtze AE, Zhou Q. Lipid nanoparticles─from liposomes to mRNA vaccine supply, a panorama of analysis range and development. ACS Nano. 2021;15:16982–7015.
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for most cancers remedy. Adv Drug Deliv Rev. 2014;66:110–6.
Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene supply. J Management Launch. 2006;114:100–9.
Filion MC, Phillips NC. Toxicity and immunomodulatory exercise of liposomal vectors formulated with cationic lipids towards immune effector cells. Biochem Biophys Acta. 1997;1329:345–56.
El Moukhtari SH, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-León A, Prosper F, et al. Lipid nanoparticles for siRNA supply in most cancers therapy. J Management Launch. 2023;361:130–46.
Yonezawa S, Koide H, Asai T. Latest advances in siRNA supply mediated by lipid-based nanoparticles. Adv Drug Deliv Rev. 2020;154:64–78.
Schlich M, Palomba R, Costabile G, Mizrahy S, Pannuzzo M, Peer D, et al. Cytosolic supply of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med. 2021;6: e10213.
Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, et al. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based remedies for power HBV an infection. J Hepatol. 2016;64:547–55.
Watanabe T, Hatakeyama H, Matsuda-Yasui C, Sato Y, Sudoh M, Takagi A, et al. In vivo therapeutic potential of Dicer-hunting siRNAs concentrating on infectious hepatitis C virus. Sci Rep. 2014;4:4750.
Eley T, Russ R, Streinu-Cercel A, Gane EJ, Roberts SK, Ahn SH, et al., editors. Pharmacokinetics and exploratory exposure-response of siRNAs administered month-to-month as ARB-001467 (ARB-1467) in a Section 2a examine in HBeAg constructive and destructive virally suppressed topics with power hepatitis B. Hepatology (Baltimore, Md); 2017: WILEY 111 RIVER ST, HOBOKEN 07030–5774, NJ USA.
Durantel D. New remedies to succeed in useful remedy: virological approaches. Greatest Pract Res Clin Gastroenterol. 2017;31:329–36.
Urits I, Swanson D, Swett MC, Patel A, Berardino Okay, Amgalan A, et al. A evaluate of patisiran (ONPATTRO®) for the therapy of polyneuropathy in folks with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301–15.
Hashimoto S, Shirasaki T, Yamashita T, Iwabuchi S, Suzuki Y, Takamura Y, et al. DOCK11 and DENND2A play pivotal roles within the upkeep of hepatitis B virus in host cells. PLoS ONE. 2021;16: e0246313.
Huang Y, Zheng S, Guo Z, de Mollerat du Jeu X, Liang X-J, Yang Z, et al. Ionizable liposomal siRNA therapeutics allows potent and protracted therapy of Hepatitis B. Sign Transduct Goal Ther. 2022;7:38.
Gao L, Yang J, Feng J, Liu Z, Dong Y, Luo J, et al. PreS/2-21-guided siRNA nanoparticles goal to inhibit hepatitis B virus an infection and replication. Entrance Immunol. 2022;13: 856463.
Miller JB, Kos P, Tieu V, Zhou Okay, Siegwart DJ. Improvement of cationic quaternary ammonium sulfonamide amino lipids for nucleic acid supply. ACS Appl Mater Interfaces. 2018;10:2302–11.
Kumar Okay, Maiti B, Kondaiah P, Bhattacharya S. Efficacious gene silencing in serum and vital apoptotic exercise induction by survivin downregulation mediated by new cationic gemini tocopheryl lipids. Mol Pharm. 2015;12:351–61.
Hean J, Crowther C, Ely A, Ul Islam R, Barichievy S, Bloom Okay, et al. Inhibition of hepatitis B virus replication in vivo utilizing lipoplexes containing altritol-modified antiviral siRNAs. Artif DNA. 2010;1:17–26.
Yang J, Zhang Q, Chang H, Cheng Y. Floor-engineered dendrimers in gene supply. Chem Rev. 2015;115:5274–300.
Wang H, Zhang S, Lv J, Cheng Y. Design of polymers for siRNA supply: latest progress and challenges. View. 2021;2:20200026.
Blakney AK, Zhu Y, McKay PF, Bouton CR, Yeow J, Tang J, et al. Huge is gorgeous: enhanced saRNA supply and immunogenicity by a better molecular weight, bioreducible, cationic polymer. ACS Nano. 2020;14:5711–27.
Park TG, Jeong JH, Kim SW. Present standing of polymeric gene supply methods. Adv Drug Deliv Rev. 2006;58:467–86.
Wahane A, Waghmode A, Kapphahn A, Dhuri Okay, Gupta A, Bahal R. Position of lipid-based and polymer-based non-viral vectors in nucleic acid supply for next-generation gene remedy. Molecules. 2020;25:2866.
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug supply units. J Management Launch. 2001;70:1–20.
Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable managed drug supply provider. Polymers. 2011;3:1377–97.
Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro applied sciences for delivering macromolecular therapeutics utilizing poly(D, L-lactide-co-glycolide) and its derivatives. J Management Launch. 2008;125:193–209.
Gary DJ, Puri N, Gained YY. Polymer-based siRNA supply: views on the elemental and phenomenological distinctions from polymer-based DNA supply. J Management Launch. 2007;121:64–73.
Aghamiri S, Jafarpour A, Gomari MM, Ghorbani J, Rajabibazl M, Payandeh Z. siRNA nanotherapeutics: a promising technique for anti-HBV remedy. IET Nanobiotechnol. 2019;13(5):457–63. https://doi.org/10.1049/iet-nbt.2018.5286.
Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly(D, L-lactide-co-glycolide) nanospheres for plasmid DNA supply and HBV gene-silencing. Int J Pharm. 2011;415:259–66.
Hou B, Qin L, Huang L. Liver most cancers cells because the mannequin for growing liver-targeted RNAi therapeutics. Biochem Biophys Res Commun. 2023;644:85–94.
Matsuda S, Keiser Okay, Nair JK, Charisse Okay, Manoharan RM, Kretschmer P, et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked by way of nucleosides elicit sturdy gene silencing in vivo in hepatocytes. ACS Chem Biol. 2015;10:1181–7.
Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, et al. Focused supply of antisense oligonucleotides to hepatocytes utilizing triantennary N-acetyl galactosamine improves efficiency 10-fold in mice. Nucleic Acids Res. 2014;42:8796–807.
Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel M-L, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol. 2015;63:1093–102.
Yu X, Lengthy Q, Shen S, Liu Z, Chandran J, Zhang J, et al. Screening of an epigenetic compound library identifies BRD4 as a possible antiviral goal for hepatitis B virus covalently closed round DNA transcription. Antiviral Res. 2023;211: 105552.
Martinelli DD. Machine studying for siRNA effectivity prediction: a scientific evaluate. Well being Sci Rev. 2024;11: 100157.
Jadhav V, Vaishnaw A, Fitzgerald Okay, Maier MA. RNA interference within the period of nucleic acid therapeutics. Nat Biotechnol. 2024;42:1–12.
Tang Q, Khvorova A. RNAi-based drug design: concerns and future instructions. Nat Rev Drug Discov. 2024;23:1–24.
